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Abstract
Background: High-intensity focused ultrasound (HIFU) is a noninvasive technique used in the treatment of early-stage
breast cancer and benign tumors. To facilitate its translation to the clinic, there is a need for a simple, cost-effective
device that can reliably monitor HIFU treatment. We have developed harmonic motion imaging (HMI), which can be
used seamlessly in conjunction with HIFU for tumor ablation monitoring, namely harmonic motion imaging for
focused ultrasound (HMIFU). The overall objective of this study was to develop an all ultrasound-based system for
real-time imaging and ablation monitoring in the human breast in vivo.
Methods: HMI was performed in 36 specimens (19 normal, 15 invasive ductal carcinomas, and 2 fibroadenomas)
immediately after surgical removal. The specimens were securely embedded in a tissue-mimicking agar gel matrix
and submerged in degassed phosphate-buffered saline to mimic in vivo environment. The HMI setup consisted
of a HIFU transducer confocally aligned with an imaging transducer to induce an oscillatory radiation force and
estimate the resulting displacement.
Results: 3D HMI displacement maps were reconstructed to represent the relative tissue stiffness in 3D. The average
peak-to-peak displacement was found to be significantly different (p = 0.003) between normal breast tissue and
invasive ductal carcinoma. There were also significant differences before and after HMIFU ablation in both the
normal (53.84 % decrease) and invasive ductal carcinoma (44.69 % decrease) specimens.
Conclusions: HMI can be used to map and differentiate relative stiffness in postsurgical normal and pathological
breast tissues. HMIFU can also successfully monitor thermal ablations in normal and pathological human breast
specimens. This HMI technique may lead to a new clinical tool for breast tumor imaging and HIFU treatment monitoring.
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Background
Breast cancer is the most common cancer and the sec-
ond leading cause of cancer death among women. In the
United States in 2013, approximately 300,000 women
were diagnosed with breast cancer and almost 40,000
died due to the disease [1]. Image-guided minimally in-
vasive treatment of localized breast tumors has become
a subject of intensive research, and researchers in several
studies have assessed the feasibility of minimally invasive
breast tumor ablation techniques, such as radiofre-
quency ablation (RFA), cryoablation, and high-intensity
focused ultrasound (HIFU) ablation [2]. Minimally inva-
sive treatments apply extreme temperatures, either high
or low, to induce irreversible cell injury, tumor apop-
tosis, and coagulative necrosis [3]. Compared with con-
ventional surgical procedures, the main advantages of
minimally invasive ablation lie in the fact that they are
less invasive, less scarring, and less painful, allowing for
shorter recovery time [4].
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HIFU is an entirely noninvasive technique, in which
the ultrasound beam is focused on a small target volume
to reach high focal power, resulting in temperature ele-
vations causing coagulative necrosis in the target while
surrounding structures are spared. Since the ultrasound
wave penetrates through soft tissue without any surgical
incision or needle insertion, there is no damage to the
skin or underlying tissues. Acoustic energy can induce
temperature elevations at the focal spot in a few seconds
and can simultaneously induce cell death and vascular
destruction in normal and tumor tissues [5]. Because of
the steep thermal gradients involved, the boundaries of
the ultrasound-treated volumes can be closely spaced
until the entire target is covered.
Clinically, fibroadenoma (FA) is the most common be-
nign breast mass and may be accompanied by pain [6].
FA does not require treatment; however, palpable FA
may cause distress in some patients, who then may re-
quest removal. Compared with conventional surgical ex-
cision or other minimally invasive techniques, HIFU is
completely noninvasive, which provides better cosmetic
results and shorter recovery time. Recently, a multicen-
ter study was conducted, in which HIFU was performed
as an outpatient procedure in 42 women with 51 FAs
[7]. The researchers demonstrated that HIFU is effective
in reducing the volume and other clinical symptoms of
FA. HIFU has also been studied for ablation of early-
stage malignant breast tumors in elderly patients who
are not surgery candidates [8–10].
Currently, magnetic resonance imaging (MRI) and
sonography are being used for guidance and monitoring
of HIFU therapy. Both magnetic resonance-guided high-
intensity focused ultrasound (MRgFUS) [11, 12] and
ultrasound-guided high-intensity focused ultrasound
(USgFUS) methods have their advantages and disadvan-
tages. MRI has the advantage of providing temperature
data within seconds after HIFU exposure. However, MRI
guidance is expensive and lengthy. Ultrasonic guidance
provides the benefit of imaging using the same form of
energy that is being used for therapy. Therefore, if the
target can be well-visualized with sonography, then the
HIFU therapy may avoid potentially causing thermal in-
jury to normal tissue. Worldwide, thousands of patients
with uterine fibroids, liver cancer, breast cancer, pancre-
atic cancer, bone tumors, and renal cancer have been
treated with USgFUS [13–15].
Ultrasound elasticity imaging is used in addition to
traditional B-mode ultrasound as a tool for differential
diagnosis between normal and tumor tissue in the hu-
man breast, based on tissue stiffness. Qualitative and
quantitative tissue strain analyses using acoustic radi-
ation force impulse (ARFI) imaging technology has been
developed for the diagnosis of breast masses [16–18].
The response of tissue to the acoustic radiation force is
tracked as tissue displacement, which has been found to
be correlated with local stiffness of the tissue. Vibro-
acoustic tissue mammography is also a radiation force-
based method that uses focused ultrasound to vibrate
tissue (in kilohertz), and uses the resulting response to
produce images that are related to the hardness of the
tissue [19, 20]. Supersonic shear imaging uses a very fast
(5000 frames/second) acquisition sequence to capture
the propagation of shear waves [21] that provide infor-
mation on the local viscoelastic properties [22, 23].
Over the past decade, ultrasound elasticity imaging
has not been limited to the area of disease diagnosis but
has also emerged in the application of therapy guidance
and monitoring [24, 25]. Past studies include but are not
limited to elastography for HIFU treatment [26–33].
Harmonic motion imaging (HMI) is an all-ultrasound-
based elasticity imaging technique designed for both re-
liable diagnosis and HIFU treatment monitoring. It uses
a HIFU transducer to emit an amplitude-modulated
(AM) beam for thermal therapy while inducing a stable
oscillatory tissue displacement at its focal zone. The os-
cillatory response, namely HMI displacement, is esti-
mated using the radiofrequency (RF) signals recorded
during the HIFU treatment through a confocally aligned
imaging transducer [34, 35]. The localized tissue re-
sponse is monitored continuously from the onset of
HIFU treatment and is aimed at providing clinicians the
change in local tissue stiffness to prevent any under- or
overtreatment. Since HMI does not interrupt HIFU abla-
tion, HIFU sonication was operated with a duty cycle of
100 %. Several studies have been published as feasibilities
ex vivo [36, 37], and in vivo [38, 39] using 1D [40] and 2D
[41] systems. The overall goal of this study was to develop
and test an HMI system for real-time imaging and abla-
tion monitoring in postsurgical breast specimens.
Methods
Collection and handling of postsurgical breast speci-
mens were approved by the institutional review board
of Columbia University, and informed consent was ob-
tained from all enrolled patients. Thirty-eight tissue
specimens were obtained from 24 patients who under-
went lumpectomy or mastectomy, including 19 normal,
15 invasive ductal carcinomas (IDCs), and 2 FAs. The
age range of the patients was 21–89 years (mean age
60 ± 18 years). All specimens were immediately
immersed in PBS after surgery and transported in ice.
The specimens used for the experiments were approxi-
mately 2 cm × 2 cm × 1 cm in size and were received
from the Department of Pathology at Columbia Univer-
sity Medical Center. Specimens were embedded in agar
gel matrix soaked in degassed PBS in a water tank, as
shown in Fig. 1. The tank wall was lined with a layer of
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sound-absorbing material to reduce undesired echoes
from below.
HMI
HMI measures the vibrational response of the target re-
gion to an oscillatory radiation force. The radiation force
is caused by the change in momentum of the acoustic
wave as it propagates through a medium. In an attenuat-
ing homogeneous medium, and assuming plane wave




where F is a volumic force (N/m3), α is the tissue ab-
sorption coefficient (m−1), I is the temporal average
acoustic intensity (W/m2), and c is the speed of sound
[m/second]. When an AM waveform is used to drive the
focused ultrasound (FUS) transducer, the radiation force
is oscillating at the modulation frequency ωm, which is
25 Hz in this study. In HMI, an oscillatory response is
induced at the HIFU focal zone due to the AM-HIFU
excitation, namely the HMI displacement. This HMI dis-
placement can be monitored throughout the entire
HIFU treatment duration. The change of the peak-to-
peak HMI displacement amplitude can be correlated
with the relative change in local tissue stiffness as the
thermal lesion develops.
A schematic illustration of the main components of
the HMI system is shown in Fig. 1. HMI was performed
using both 1D and 2D HMI systems in this study. The
1D HMI system was comprised of a single-element FUS
transducer (outer diameter 80 mm, inner diameter 16.5
mm, center frequency 4.75 MHz, focal depth 90 mm;
Riverside Research Institute, New York, NY, USA)
coaligned with a single-element pulse-echo transducer
(diameter 15 mm, center frequency 7.5 MHz, focal depth
60 mm; Olympus-NDT, Waltham, MA, USA) (Fig. 1).
The FUS transducer was driven by an amplitude-
modulated (AM frequency ωm 25 Hz) sinusoidal signal
generated by a dual-channel arbitrary waveform gener-
ator (AT33522A; Agilent Technologies Inc., Santa Clara,
CA, USA) and amplified by a nominal 50-dB gain power
amplifier (325LA; Electronics & Innovation [E&I], Roch-
ester, NY, USA). The pulse-echo transducer was
mounted through the center hole of the FUS transducer
and confocally aligned with it. It was connected to a
pulser-receiver (Olympus-NDT) operating at 1 kHz. The
received RF signals from the pulser-receiver were band-
pass filtered (Reactel Inc., Gaithersburg, MD, USA) with
cutoff frequencies of fc1 = 5.84 MHz and fc2 = 8.66 MHz
and then recorded with a digitizer (GaGe; Dynamic-
Signals, Lockport, IL, USA) at a sampling frequency of
100 MHz. To generate a 3D HMI displacement map,
point-by-point raster scan acquisition was used with a
step size of 0.5 mm in transverse plane. At each spot,
the FUS exposure was 0.6 seconds long (30-cycle oscilla-
tions at 50 Hz), during which 600 RF lines at 1-kHz
pulse repetition frequency were acquired.
The 2D HMI system consisted of a 93-element FUS
phased array transducer (individual element diameter 10
Fig. 1 Schematic of harmonic motion imaging (HMI) system with experiment setup. a Block diagram of HMI system. The red region indicates the
focus of the focused ultrasound (FUS) transducer. b The 1D HMI system comprised of a single-element FUS transducer (outer diameter 80 mm,
inner diameter 16.5 mm) coaligned with a single-element pulse-echo transducer (diameter 15 mm). c The 2D HMI system consisted of a 93-element
FUS phase array transducer (outer diameter 110 mm, inner diameter 41 mm) and a 64-element phase array imaging probe
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mm, overall outer diameter 110 mm, inner diameter 41
mm, center frequency 4.5 MHz, focal depth 70 mm, H-
178; Sonic Concepts Inc., Bothell, WA, USA) and a 64-
element phase array imaging probe (center frequency 2.5
MHz, P4-2; ATL Ultrasound, Bothell, WA, USA) (Fig. 1).
In this feasibility study, the 93-element FUS transducer
was driven in phase using the same function generator
and power amplifier as the 1D system. The imaging
probe was inserted through an opening in the center of
the FUS transducer and confocally aligned with it. The
imaging probe was operated with an ultrasound imaging
research system (V-1; Verasonics, Kirkland, WA, USA).
The FUS total output acoustic power was 11 W in the
1D system and 8.7 W in the 2D system from radiation
force balance measurement [44].
Harmonic motion imaging for focused ultrasound
Harmonic motion imaging for focused ultrasound
(HMIFU) ablation monitoring was performed in 19 nor-
mal, 15 IDC, and 2 FA specimens using either a 1D or
2D HMI system, and each specimen was ablated at one
or two different targeted locations, depending on the
size of the specimen. Before HIFU ablation, a standard
B-mode image of the targeted region was acquired using
the imaging probe. Then HIFU was applied for a total
duration of 120 seconds in a single location. Since
HMIFU does not require interruption of HIFU ablation,
HIFU sonication was operated with a duty cycle of 100
%. A customized plane wave imaging sequence was de-
veloped using the Verasonics Data Acquisition System
platform. A GPU-based sparse-matrix algorithm was
used for fast beamforming. During HMIFU exposure,
200 beamformed frames at a frame rate of 1 kHz were
acquired and transferred to the host workstation every 3
seconds. An interpolation was performed to upsample
the RF signals by a factor of 8 to achieve a sampling fre-
quency of 80 MHz before storing the RF signals on the
host workstation. After 120 seconds of continuous HIFU
ablation, a total of 40 datasets were acquired. The main
parameters of the two systems are summarized in Table 1.
HMI displacement estimation
The signal processing techniques were the same for the
1D and 2D HMI systems. Each set of continuously ac-
quired RF lines using the 1D HMI system, or each set of
the 200 continuously acquired RF frames using the 2D
HMI system, was processed together. The interference
of the FUS beam with the RF signals was removed by
digital low-pass filtering (fcutoff = 4 MHz) during pro-
cessing using the 2D system. In the 1D system, the inter-
ference of the FUS beam was removed by the analog
band-pass filter as described previously. The incremental
axial tissue displacements were estimated by performing
a fast 1D normalized cross-correlation between sequen-
tially acquired tracking lines [45]. The RF window size
was equal to 5 wavelengths of the imaging probe, and
the window overlap was 95 %. A threshold (R2 > 0.7) was
applied to eliminate poor displacement estimation. The
mean peak-to-peak HMI displacement amplitudes and
standard deviation of the 10-cycle oscillations at 50 Hz
were calculated based on the 200 RF lines or frames.
The aforementioned processing was repeated at each
raster scan point to obtain the 3D HMI displacement
image for breast tumor detection.
For HMIFU ablation monitoring, the mean and
standard deviation of the peak-to-peak amplitude of
the estimated HMI displacements within the region of
interest (ROI) were analyzed for the whole HMIFU
ablation process. To compare different targeted loca-
tions, normalization of the HMI displacements by the
displacement obtained at t = 2 seconds was performed.
Changes in the HMI displacement amplitude were
calculated by the percentage change in HMI displace-
ment at the end of the thermal treatment over the
displacement at t = 2 seconds.
A focal spot localization method [37] was used to de-
fine the ROI. A maximum peak-to-peak displacement
Table 1 Main parameters of 1D and 2D HMI/HMIFU systems
1D HMI/HMIFU 2D HMI/HMIFU
FUS transducer 4.75-MHz single-element transducer 4.5-MHz 93-element FUS phased array
Imaging transducer 7.5-MHz single-element pulse-echo transducer 2.5-MHz 64-element phased array
Parameters
AM frequency 25 Hz 25 Hz
Sampling frequency 100 MHz 80 MHz
Frame rate 1000 Hz 1000 Hz
Acoustic power 11 W 8.7 W
Imaging duration 0.6 seconds 0.6 seconds
Ablation duration 120 seconds 120 seconds
AM amplitude-modulated, FUS focused ultrasound, HMI harmonic motion imaging, HMIFU harmonic motion imaging for focused ultrasound
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value was estimated along the axial direction (1D) or the
image (2D). On the basis of the maximum peak-to-peak
displacement value, we calculated a −3 dB displacement
focal zone over the axial direction (1D) or the image
(2D). To quantitatively analyze the relative tissue stiff-
ness change during heating, the resulting displacement
around the focal region was then averaged within the −3
dB region.
3D data rendering (Fig. 2b, d, f ) was achieved using
Amira software (FEI, Hillsboro, OR, USA). MATLAB
software (MathWorks, Natick, MA, USA) was used for
the statistical analysis. The results were presented in
Fig. 2 3D harmonic motion imaging (HMI) displacement images of normal breast, invasive ductal carcinoma (IDC), and fibroadenoma (FA) tissue.
a Gross pathology photograph of a normal breast specimen mounted on the gel matrix. The 3D reconstructed HMI of the selected tissue is shown
(b) before and (c) after harmonic motion imaging for focused ultrasound (HMIFU) ablation. d Gross pathology photograph of a IDC specimen
mounted on the gel matrix. The 3D reconstructed HMI of the selected tissue is shown (e) before and (f) after HMIFU ablation. g Gross pathology
photograph of an FA specimen mounted on the gel matrix. The 3D reconstructed HMI of the selected tissue is shown (h) before and (i) after
HMIFU ablation. The brighter the color, the higher the HMI displacement and the lower relative stiffness, and vice versa
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mean ± standard deviation format. A paired Student’s t
test was used to determine a significant difference
(p < 0.05) between before and after ablation.
Histology
The specimens were kept in 10 % phosphate-buffered
formalin at low temperature (4 °C) for at least 24 h. The
specimens were then processed and embedded in paraf-
fin, cut into 4-μm-thick slices, and stained with
hematoxylin and eosin (H&E).
Results
HMI
In Fig. 2, 3D HMI images of a normal breast specimen,
a breast tumor specimen, and an FA specimen before
and after HMIFU ablation are shown in comparison
with gross pathology images. In the 1D system, the HMI
displacement amplitudes of the normal breast, IDC, and
FA tissue averaged within the −3 dB regions were 40.10
± 15.50 μm (n = 9), 24.90 ± 9.64 μm (n = 5), and 7.40 μm
(n = 1), respectively (Fig. 3a). With the 2D system, the
corresponding values were 24.73 ± 10.97 μm (n = 10),
12.77 ± 10.30 μm (n = 10), and 2.56 μm (n = 1) (Fig. 3b).
In histological analysis, we found no tissue damage in
the normal breast, IDC, or FA tissue on the basis of
HMI imaging alone.
HMIFU ablation monitoring
Figure 3 shows HMI displacement change before and
after HIFU ablation using the 1D (Fig. 3a) and 2D
(Fig. 3b) systems. Tissue motion during heating is visible
through the periodic variation in displacement ampli-
tude, which is denoted by alternating red (positive) and
blue (negative) displacement in Fig. 3. Red denotes the
highest motion towards the transducer, and blue repre-
sents the highest motion away from the transducer.
Using the 1D HMI system, nine (100 %) out of nine nor-
mal breast lesions, five (100 %) out of five IDC lesions,
and one (100 %) out of one FA lesions were found to
have lower HMI displacement amplitude after HMIFU
treatment, indicating protein denaturation and necrosis.
Using the 2D HMI system, nine (90 %) out of ten nor-
mal breast lesions, eight (80 %) out of ten IDC lesions,
and one (100 %) out of one FA lesions were found to
have lower HMI displacement after HMIFU treatment.
HMI displacement before and after HMIFU ablation
were compared by performing a paired Student’s t test.
The mean HMI displacement before and after ablation is
shown in Table 2.
The mean HMI displacement of the normal breast tis-
sue decreased from 40.10 ± 15.50 μm to 17.49 ± 7.85 μm
(n = 9, p = 0.0025) using the 1D system and from 24.73
± 10.97 μm to 9.83 ± 6.46 μm (n = 10, p = 0.0048) using
the 2D system. The mean HMI displacement of IDC
decreased from 24.90 ± 9.64 μm to 12.28 ± 5.44 μm (n = 5,
p = 0.0068) using the 1D system and from 12.77 ± 3.50 μm
to 5.35 ± 2.74 μm (n = 10, p = 0.045) using the 2D system.
The mean HMI displacement of FA decreased from 7.34
μm to 6.58 μm (n = 1) using the 1D system and from 2.56
μm to 2.06 μm (n = 1) using the 2D system. A similar de-
crease was also clearly observed in 2D, where the individ-
ual frameset consisted of peak negative displacement
profiles (Fig. 4) as an example of a treated location.
The normalized HMI displacement change over the
entire HMIFU ablation process in all specimens is
shown in Table 3. Compared with the initial displace-
ment at the beginning (t = 2 seconds), HMI displacement
at the end (t = 118 seconds) of the HIFU ablation was
observed. The HMI displacement amplitudes in normal
breast and IDC tissue were 53.84 % and 44.69 % lower,
respectively, at the end of the 2-minute HMIFU treat-
ment compared with those at the beginning of HMIFU
exposure, showing consistent stiffening after HMIFU ab-
lation. The representative H&E staining results after
HMIFU are shown in Fig. 5. Characteristic and similar
histologic changes are seen in normal breast paren-
chyma, FA, or IDC (i.e., all tissues exposed to HIFU).
The sections showed discrete hypereosinophilic areas
reflecting changes occurring in the collagenous stroma
as well as cautery-like “streaming” phenomena in the
HIFU-ablated epithelial regions. The changes seen in
the epithelium and/or nuclei were (nonneoplastic, be-
nign, or malignant) reminiscent of what is seen in tis-
sue exposed to electrocautery change. The surrounding
tissues were histologically unchanged.
Discussion
The clinical application of HIFU in tumor treatment is
currently hampered by the lack of a simple, cost-
effective device to reliably monitor HIFU treatment that
can be used at the point of care. Experimental HMI im-
ages presented in this study demonstrate two important
facts: (1) HMI is capable of detecting and imaging breast
tumors in situ, and (2) HMIFU provides the capability of
monitoring tissue stiffness changes while simultaneously
probing and forming lesions within the breast tissue.
It was found that HMI displacement amplitudes in the
IDC and FA were, on average, 43 % and 85 % lower, re-
spectively, than that in the normal breast. Although the
tissue elasticity cannot be directly measured, this dis-
placement contrast ratio can be indexed for relative
stiffness of different types of tissues in the breast, con-
sidering that a similar level of radiation force was ap-
plied. Histological analysis shows that, in the setting of
low FUS exposure during tumor detection, no tissue
damage is found, which demonstrates that HMI can be
performed without causing tissue damage.
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Besides tumor detection, HMI offers unique solutions
for HIFU tumor ablation monitoring. In this study, for
the thermal treatment of tumors ex vivo, an acoustic
power of 11 W or 8.7 W and a duration of exposure of
120 seconds for each location were used. Significant re-
duction (53.84 % decrease in normal tissue and 44.69 %
decrease in IDC tissue) in the HMI displacement ampli-
tude in the tumor after HIFU ablation was observed.
This indicates that the HIFU-induced lesions could be
detected through the reduction in the harmonic motion
amplitude. HMI monitors lesion formation based on the
underlying tissue stiffness changes. Therefore, it can be
Fig. 3 Harmonic motion imaging (HMI) displacement change between before and after ablation. a Nine normal, five invasive ductal carcinoma
(IDC), and one fibroadenoma (FA) specimens were imaged with the 1D HMI system. b Ten normal, ten IDC, and one FA specimens were imaged with
the 2D HMI system. c Combined results with both HMI systems. *p < 0.05, **p < 0.001, and ****p < 0.00001
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Table 2 Harmonic motion imaging displacement before and after harmonic motion imaging for focused ultrasound ablation
1D system 2D system
Displacement (μm) Displacement (μm)
Before After n p value Before After n p value
Normal 40.10 ± 15.50 17.49 ± 7.85 9 0.0025 24.73 ± 10.97 9.83 ± 6.46 10 0.0048
IDC 24.90 ± 9.64 12.28 ± 5.44 5 0.0068 12.77 ± 3.50 5.35 ± 2.74 10 0.045
FA 7.34 6.58 1 2.56 2.06 1
FA fibroadenoma, IDC invasive ductal carcinoma
Fig. 4 Harmonic motion imaging for focused ultrasound (HMIFU) ablation monitoring in 2D overlaying on B-mode images in (a) normal
breast and (b) IDC tissue. Tissue motion during heating is denoted by alternating red and blue. Red represents the motion moving toward the transducer,
and blue represents the motion moving away from the transducer. Peak negative harmonic motion imaging displacement frames during a 50-Hz cycle
at five representative timepoints were selected from the HMIFU treatment monitoring sequence to show the decrease of focal displacement as the
thermal lesion forms
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more reliable than monitoring lesion formation by track-
ing the presence of cavitation or boiling bubbles, which
are by definition stochastic phenomena currently used in
the clinic for HIFU treatment monitoring [46]. We dem-
onstrated that HMI is feasible for monitoring HIFU ab-
lation in human breast tissue without interrupting HIFU
treatment.
Application of HMI for breast imaging and HIFU
monitoring is both promising and challenging. The over-
all displacement acquired with the 1D system was higher
than that acquired with the 2D system due to the acous-
tic output difference between the two systems. It may be
due to the higher efficiency of the 1D system, which
generated higher radiation force and therefore higher
displacement in the focal region. The output acoustic
power levels used in the two systems were 11 W and 8.7
W, respectively. Both systems, however, showed similar
displacement contrast between normal breast, IDC, and
FA tissues after normalization. Therefore, the power dif-
ference in this study does not influence the ability of
HMI to differentiate abnormal from normal tissues.
However, it should be noted that the very low acoustic
power output could potentially reduce the signal-to-
noise ratio with depth. Another limitation of this study
lies in the raster scanning used in the experiment for 3D
HMI. It involves a relatively lengthy process and thus is
subject to motion artifacts induced by respiratory and
cardiac motions when applied in patients. Electronic
steering of the FUS beam is being used in ongoing stud-
ies to sweep the focal spot in order to facilitate the im-
aging process. Furthermore, although offline processing
was used in this study, the 2D HMI system has the fun-
damental capability of online monitoring [41]. Ongoing
Table 3 Normalized harmonic motion imaging displacement
change over the entire ablation process
Percentage change SD
Normal −53.84 % 25.60 %
IDC −44.69 % 29.55 %
FA −15.33 % 4.26 %
FA fibroadenoma, IDC invasive ductal carcinoma
Fig. 5 Examples of hematoxylin and eosin staining of harmonic motion imaging for focused ultrasound-ablated normal breast (a–c), invasive
ductal carcinoma (d–f), and fibroadenoma (g–i) tissues. In (a), (d), and (g), scale bars indicate 4 mm; in the rest of the images, scale bars indicate 0.1
mm. In (b), (e), and (h), high-magnification images display unablated regions taken within the corresponding black frames. In (c), (f), and (i) high-
magnification images display ablated regions taken within the corresponding blue frames. The ablated regions show discrete hypereosinophilic areas
reflecting changes occurring in the collagenous stroma as well as cautery-like “streaming” phenomena (arrows) in the HIFU-ablated epithelial regions.
The changes seen in the epithelium and/or nuclei are (nonneoplastic, benign, or malignant) reminiscent of what is seen in tissue exposed to electrocautery
change. Surrounding tissues remained histologically intact
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work explores the potential of using HMI to provide
feedback control of the HMIFU ablation to control
HMIFU therapy.
Last, 2D HMI clearly located the HMIFU focal region
and monitored the stiffness change of the focal region
over time. However, because of the difficulty involved in
sectioning through the excised breast to coregister with
the imaging plane of the HMI, precise quantitative com-
parisons of actual lesion size and HMI displacement im-
ages cannot be performed with high confidence. To
assess the thermal lesion size on the basis of HMI im-
ages, additional studies are needed to correlate the HMI
displacement map with histological measurements and
to define a quantitative threshold in HMIFU displace-
ment change that corresponds to lesion formation,
allowing physicians to easily identify the onset of lesion
formation. The correlation between tissue structures and
HMI characteristics will also be considered in future
studies to improve understanding of tissue mechanical
responses during HMIFU ablation.
HIFU has been available in the United States to treat
uterine fibroids and prostate tumors and to relieve pain
due to bone metastases. Moreover, there is a growing
number of clinical applications at various stages of re-
search and development around the world, including
breast cancer [47], pancreatic cancer [48], and brain tu-
mors [49]. MRgFUS has the advantage of high spatial
resolution with thermometry capability. However, the in-
trinsic low frame rate of MRI prohibits real-time moni-
toring of the treatment. On the other hand, USgFUS
allows for real-time imaging at a relatively low cost. Dif-
ferent from conventional B-mode monitoring, which re-
lies on the appearance of hyperechoic spots resulting
from boiling, HMIFU can provide relative tissue stiffness
changes in real-time without interfering with the HIFU
treatment. Future clinical HMIFU could thus be used in
an outpatient setting. In addition to its relatively low as-
sociated costs, HMIFU will also be characterized by its
noninvasive nature and reduced adverse effects.
The present study lays the foundation for future devel-
opment of HMI as a clinical monitoring technique for
breast HIFU with the added capability of detecting tu-
mors for treatment planning, evaluation of tissue stiff-
ness changes during HIFU ablation for treatment
monitoring in real-time, and assessment of thermal le-
sion sizes after treatment evaluation.
Conclusion
In this paper, we present a noninvasive imaging method
for imaging postsurgical breast tumor specimens and
monitoring of HIFU ablation. The results of this study
indicate that breast tumors confirmed with pathology
can be detected by HMI. HMI has been shown experi-
mentally to be capable of mapping and differentiating
stiffness in normal and abnormal breast tissues. HMIFU
can also successfully generate thermal lesions on normal
and pathological breast tissues.
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